Drug delivery using polyhistidine peptide-modified liposomes that target endogenous lysosome

Hayashi, Taiki; Shinagawa, Matsumi; Kawano, Tsuyoshi; Iwasaki, Takashi

doi:10.1016/j.bbrc.2018.05.037

Cited by 26 publications

(13 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We previously showed that His16 peptide alone and His16 peptide-modified liposomes were localized to intracellular lysosomes in HT1080 cells [3,4]. Therefore, we examined the colocalization between His16-Lyso and endogenous lysosomes.…”

Section: Resultsmentioning

confidence: 99%

“…Previously, we reported that cellular uptake of His16 peptide was not affected by serum [3], although serum is known to exhibit ionic interactions with cationic CPPs and dramatically suppress their cellular uptake [25,26]. In another study, we showed that cellular uptake of His16 peptide-modified liposomes was slightly enhanced in the presence of serum [4]. Thus, increased membrane vesicle transport by His16 peptide with serum can explain the observed stable cellular uptake of His16-Lyso in the presence of serum, and this is a useful feature for in vivo ERT.…”

Section: Resultsmentioning

confidence: 99%

“…FD is caused by loss of galactosidase alfa (GLA), a type of lysosomal enzyme [27]. GLA-knockdown cells were reported to show slower cell proliferation than normal cells [4,27]. Therefore, we evaluated the ERT efficacy of His16-Lyso against FD patient fibroblasts by measuring cell proliferation recovery.…”

Section: Resultsmentioning

confidence: 99%

“…Our previous study showed that His16 peptide fused to both small molecules and macromolecules localized to lysosomes in mammalian cells [3]. These features led us to consider the application of His16 peptide as a DDS carrier targeting intracellular lysosomes, and we subsequently reported a lysosome-targeting DDS using His16 peptide-modified liposomes [4]. Therefore, His16 peptide is anticipated to be a new carrier for DDSs targeting intracellular lysosomes.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Development of Organelle Replacement Therapy Using a Stearyl-Polyhistidine Peptide against Lysosomal Storage Disease Cells

et al. 2019

View full text Add to dashboard Cite

We previously reported on a polyhistidine peptide, His16 peptide, as a new cell-penetrating peptide. This peptide is anticipated to be a new carrier for drug delivery systems (DDSs) for targeting intracellular lysosomes because it can transport macromolecules (e.g., liposomes) into these organelles. In the present study, we examined the application of His16 peptide as a DDS carrier against lysosomal storage disease (LSD) cells. LSDs are metabolic disorders caused by loss of specific lysosomal enzymes. For the treatment of LSD cells, we devised a system designated organelle replacement therapy (ORT). ORT is a strategy for transporting exogenous lysosomes containing all kinds of lysosomal enzymes from normal cells into endogenous lysosomes in LSD cells using His16 peptide. To develop the ORT system, we prepared His16 peptide-modified healthy lysosomes (His16-Lyso) by insertion of a stearyl-His16 peptide into a hydrophobic region in the lysosomal membrane. His16-Lyso showed cellular uptake and localization to endogenous lysosomes in LSD cells. His16-Lyso also restored the proliferation of LSD cells, which otherwise showed slower proliferation than normal cells. These results suggested that His16-Lyso replenished deficient lysosomal enzymes in LSD cells. The results further suggest that His16-Lyso are promising candidates as a treatment tool for LSD cells and to establish a foundation for ORT.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Development of Organelle Replacement Therapy Using a Stearyl-Polyhistidine Peptide against Lysosomal Storage Disease Cells

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The triblock copolymers afterwards functionalized with biotin for targeted delivery, exhibiting a remarkable impact on the obstruction of P-gp ATPase activity of MCF-/ADR cells, the reduction of intracellular ATP level and, the loss of mitochondrial membrane potential [84]. The use of pHis-modified liposomes as a cell penetrating vehicle to deliver the large cargos such as α-galactoseidase A, a lysosomal enzyme to the intracellular lysosomes was also attempted [85]. The hydrogel based on multivalent coordination of Ni 2+ with pHis-terminated PEG and multiple iminodiacetic acid-modified oligochitosan that shows enhanced neutral stability was used as a pH-responsive self-healing system [86].…”

Section: Types Of Ph-responsive Polypeptidesmentioning

confidence: 99%

pH-Responsive Polypeptide-Based Smart Nano-Carriers for Theranostic Applications

et al. 2019

View full text Add to dashboard Cite

Smart nano-carriers have attained great significance in the biomedical field due to their versatile and interesting designs with different functionalities. The initial stages of the development of nanocarriers mainly focused on the guest loading efficiency, biocompatibility of the host and the circulation time. Later the requirements of less side effects with more efficacy arose by attributing targetability and stimuli-responsive characteristics to nano-carriers along with their bio- compatibility. Researchers are utilizing many stimuli-responsive polymers for the better release of the guest molecules at the targeted sites. Among these, pH-triggered release achieves increasing importance because of the pH variation in different organ and cancer cells of acidic pH. This specific feature is utilized to release the guest molecules more precisely in the targeted site by designing polymers having specific functionality with the pH dependent morphology change characteristics. In this review, we mainly concert on the pH-responsive polypeptides and some interesting nano-carrier designs for the effective theranostic applications. Also, emphasis is made on pharmaceutical application of the different nano-carriers with respect to the organ, tissue and cellular level pH environment.

show abstract

Cationic Peptide

Iwasaki

2022

Cell‐Penetrating Peptides

View full text Add to dashboard Cite

Drug delivery using polyhistidine peptide-modified liposomes that target endogenous lysosome

Cited by 26 publications

References 20 publications

Development of Organelle Replacement Therapy Using a Stearyl-Polyhistidine Peptide against Lysosomal Storage Disease Cells

Development of Organelle Replacement Therapy Using a Stearyl-Polyhistidine Peptide against Lysosomal Storage Disease Cells

pH-Responsive Polypeptide-Based Smart Nano-Carriers for Theranostic Applications

Cationic Peptide

Contact Info

Product

Resources

About